Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10068
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHowden, Benjamin Pen
dc.contributor.authorGrayson, M Lindsayen
dc.date.accessioned2015-05-15T23:24:17Z
dc.date.available2015-05-15T23:24:17Z
dc.date.issued2005-12-15en
dc.identifier.citationClinical Infectious Diseases 2005; 42(3): 394-400en
dc.identifier.govdoc16392088en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10068en
dc.description.abstractFusidic acid has activity against a range of pathogens but has mainly been used to treat staphylococcal infections. Fusidic acid monotherapy, especially topical preparations, has been strongly associated with the emergence of fusidic acid resistance among both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus. Key resistance determinants include mutations in the fusA gene, which encodes elongation factor G, and plasmid-mediated resistance (i.e., acquisition of resistance gene fusB). Clonal outbreaks of fusidic acid-resistant S. aureus have been noted throughout the United Kingdom and Europe, such that the efficacy of fusidic acid is threatened. Fusidic acid in combination with other agents, such as rifampicin, has proven effective for difficult-to-treat MRSA infections and provides a convenient oral alternative to oxazolidinones. Ensuring that systemic fusidic acid is always used in combination and that the use of topical fusidic acid is either abolished or restricted will be vital if we are to prevent the loss of this potentially useful agent.en
dc.language.isoenen
dc.subject.otherAnti-Bacterial Agents.pharmacologyen
dc.subject.otherDrug Resistance, Bacterialen
dc.subject.otherDrug Utilization.trendsen
dc.subject.otherFusidic Acid.pharmacologyen
dc.subject.otherHumansen
dc.subject.otherStaphylococcal Infections.drug therapy.epidemiology.microbiologyen
dc.subject.otherStaphylococcus aureus.drug effects.geneticsen
dc.titleDumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Infectious Diseasesen
dc.identifier.affiliationInfectious Diseases Department, Austin Health, Heidelberg, Victoria, 3084, Australiaen
dc.identifier.doi10.1086/499365en
dc.description.pages394-400en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/16392088en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
crisitem.author.deptInfectious Diseases-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Feb 5, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.